Citius Pharmaceuticals Inc. [NASDAQ: CTXR] jumped around 0.05 points on Thursday, while shares priced at $1.82 at the close of the session, up 2.82%. The company report on March 23, 2021 that Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25.
Mino-Lok® has the potential to change the standard of care for treating catheter-related bloodstream infections.
Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Citius Executive Chairman, Leonard Mazur, will present on Thursday, March 25 at 2:55 pm ET. Investors may register for the conference at the event website.
Citius Pharmaceuticals Inc. stock is now 78.43% up from its year-to-date (YTD) trading value. CTXR Stock saw the intraday high of $1.86 and lowest of $1.75 per share. The company’s 52-week high price is 2.90, which means current price is +82.00% above from all time high which was touched on 02/22/21.
Compared to the average trading volume of 14.50M shares, CTXR reached a trading volume of 3757981 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Citius Pharmaceuticals Inc. [CTXR]?
The Average True Range (ATR) for Citius Pharmaceuticals Inc. is set at 0.14 The Price to Book ratio for the last quarter was 4.04, with the Price to Cash per share for the same quarter was set at 0.04.
How has CTXR stock performed recently?
Citius Pharmaceuticals Inc. [CTXR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.25. With this latest performance, CTXR shares dropped by -5.21% in over the last four-week period, additionally plugging by 80.20% over the last 6 months – not to mention a rise of 173.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTXR stock in for the last two-week period is set at 48.89, with the RSI for the last a single of trading hit 46.66, and the three-weeks RSI is set at 51.08 for Citius Pharmaceuticals Inc. [CTXR]. The present Moving Average for the last 50 days of trading for this stock 1.7554, while it was recorded at 1.8060 for the last single week of trading, and 1.2603 for the last 200 days.
Citius Pharmaceuticals Inc. [CTXR]: Deeper insight into the fundamentals
Return on Total Capital for CTXR is now -59.46, given the latest momentum, and Return on Invested Capital for the company is -59.42. Return on Equity for this stock declined to -60.46, with Return on Assets sitting at -48.24. When it comes to the capital structure of this company, Citius Pharmaceuticals Inc. [CTXR] has a Total Debt to Total Equity ratio set at 4.02. Additionally, CTXR Total Debt to Total Capital is recorded at 3.86, with Total Debt to Total Assets ending up at 3.09. Long-Term Debt to Equity for the company is recorded at 3.03, with the Long-Term Debt to Total Capital now at 2.91.
Reflecting on the efficiency of the workforce at the company, Citius Pharmaceuticals Inc. [CTXR] managed to generate an average of -$1,754,808 per employee.Citius Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.
Earnings analysis for Citius Pharmaceuticals Inc. [CTXR]
With the latest financial reports released by the company, Citius Pharmaceuticals Inc. posted -0.13/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -30.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CTXR.
Insider trade positions for Citius Pharmaceuticals Inc. [CTXR]
There are presently around $4 million, or 7.00% of CTXR stock, in the hands of institutional investors. The top three institutional holders of CTXR stocks are: VANGUARD GROUP INC with ownership of 755,119, which is approximately 31.798% of the company’s market cap and around 9.80% of the total institutional ownership; HIGHTOWER ADVISORS, LLC, holding 169,944 shares of the stock with an approximate value of $0.31 million in CTXR stocks shares; and ARGENT WEALTH MANAGEMENT LLC, currently with $0.3 million in CTXR stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Citius Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 17 institutional holders increased their position in Citius Pharmaceuticals Inc. [NASDAQ:CTXR] by around 864,769 shares. Additionally, 5 investors decreased positions by around 101,943 shares, while 6 investors held positions by with 1,010,545 shares. The mentioned changes placed institutional holdings at 1,977,257 shares, according to the latest SEC report filing. CTXR stock had 11 new institutional investments in for a total of 541,481 shares, while 5 institutional investors sold positions of 101,943 shares during the same period.